PsychoGenics Appoints John McCall, Ph.D. as Newest Member to its
Scientific Advisory Board (SAB)
This Appointment Reflects the Company’s
Expansion into Drug Discovery and Development
TARRYTOWN, N.Y. (Business Wire EON/PRWEB ) August 25, 2008 --
PsychoGenics Inc., announces the appointment of John McCall, Ph.D., as a
member of its Scientific Advisory Board, reflecting the company’s
growth in the areas of Drug Discovery and Development.
Dr. McCall has over thirty years experience in the pharmaceutical
industry including senior positions held at Pfizer, as Senior Vice
President of Pfizer Global Research, Site Head for Pfizer Chicago, for
Pharmacia and Upjohn as Vice President of Global Discovery Chemistry,
Global Vice President Discovery Chemistry, and for Upjohn as Head of CNS
and Head of Chemistry. Dr. McCall is currently the President of PharMac
LLC, providing consulting services for drug discovery, project
management, project evaluation, and research organization, to the
pharmaceutical industry. He chairs the Spinal Muscular Atrophy project
for NINDS and is a partner in the Apjohn Group.
“I look forward to my contribution as an
advisor to PsychoGenics, a stimulating company with a unique and
innovative approach to drug discovery”,
commented Dr. McCall.
“We are extremely excited about John’s
addition to our SAB”, explained Dr Eric
Nestler, Scientific co-founder and Chairman of PsychoGenics’
Scientific Advisory Board, “John’s
considerable experience and expertise in drug discovery and development
will be of great value to PsychoGenics as it expands its internal and
partnered drug discovery programs”.
PsychoGenics’ SAB includes academic leaders
in their respective fields: Dr Eric Nestler, scientific co-founder of
PsychoGenics, who recently returned to New York City as Chair of
Neuroscience and Director of the Brain Institute at the Mount Sinai
School of Medicine; Dr Paul Greengard, awarded the Nobel Prize for
Medicine and Physiology in 2000, and the Vincent Astor Professor and
Head of the Laboratory of Molecular and Cellular Neuroscience at
Rockefeller University; Dr Ronald Duman, Professor of the Departments of
Psychiatry and Pharmacology at Yale University School of Medicine; Dr
Rene Hen, Professor of Pharmacology at the Columbia University Center of
Neurobiology and Behavior; Dr George Koob, Director of the Division of
Psychopharmacology at Scripps Research Institute; Dr Richard Paylor,
Professor of the Department of Molecular and Human Genetics at Baylor
College of Medicine; and Dr Berend Olivier, Director or PsychoGenics’
European Operation and Chairman and Professor of the Department of
Psychopharmacology at Utrecht University.
About PsychoGenics:
PsychoGenics is a leader in preclinical behavioral neurobiology and a
provider of customized and innovative solutions for central nervous
system (CNS) drug discovery. PsychoGenics works with pharmaceutical and
biotechnology companies, academic institutions and not-for-profit
research foundations to address such major neurological disorders as:
ALS, Huntington’s Disease, anxiety, cognitive
impairment, depression, psychosis/schizophrenia and SMA. PsychoGenics
supports the understanding and treatment of CNS disorders by offering an
extensive range of established and customized validated in vivo
behavioral tests, behavioral pharmacology, phenotyping, bioinformatics,
microdialysis and radiotelemetry.
Post Comment:
Trackback URL: http://www.prweb.com/pingpr.php/RW1wdC1aZXRhLUVtcHQtRW1wdC1QaWdnLVNpbmctWmVybw==
Bookmark -
Del.icio.us |
Furl It |
Technorati |
Ask |
MyWeb |
Propeller |
Live Bookmarks |
Newsvine |
TailRank |
Reddit |
Slashdot |
Digg |
Stumbleupon |
Google Bookmarks |
Sphere |
Blink It |
Spurl
|
Share The News
Submit this press release easily to any of these major bookmarking and social media sites.